{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:22:00Z","timestamp":1788870120183,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Cancer Institute, Department of Health and Human Services","award":["CA100632"],"award-info":[{"award-number":["CA100632"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.clml.2012.03.003","type":"journal-article","created":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T01:32:28Z","timestamp":1335231148000},"page":"244-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed\/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"12","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Plunkett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.03.003_bib1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood.V96.5.1670","article-title":"How I treat older patients with AML","volume":"96","author":"Estey","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.03.003_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1993.11.1.116","article-title":"Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy","volume":"11","author":"Gandhi","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.03.003_bib3","first-page":"169","article-title":"Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia","volume":"1","author":"Gandhi","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.03.003_bib4","first-page":"1539","article-title":"Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy","volume":"3","author":"Gandhi","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.03.003_bib5","first-page":"580","article-title":"Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia","volume":"1","author":"Estey","year":"1987","journal-title":"Leucemia"},{"key":"10.1016\/j.clml.2012.03.003_bib6","first-page":"95","article-title":"Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia","volume":"4","author":"Estey","year":"1990","journal-title":"Leucemia"},{"key":"10.1016\/j.clml.2012.03.003_bib7","first-page":"476","article-title":"Treatment of relapsed or refractory acute myelogenous leukemia","volume":"14","author":"Estey","year":"2000","journal-title":"Leucemia"},{"key":"10.1016\/j.clml.2012.03.003_bib8","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2012.03.003_bib9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.03.003_bib10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/cncr.21187","article-title":"Outcome of patients with acute myelogenous leukemia after second salvage therapy","volume":"104","author":"Giles","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2012.03.003_bib11","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1182\/blood-2010-07-296392","article-title":"Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.03.003_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/10428199309148532","article-title":"Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia","volume":"9","author":"Estey","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2012.03.003_bib13","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1002\/cncr.23927","article-title":"Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival","volume":"113","author":"Borthakur","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2012.03.003_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.leukres.2010.09.002","article-title":"Salvage chemotherapy regimens for acute myeloid leukemia: is one better?","volume":"35","author":"Price","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2012.03.003_bib15","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0145-2126(03)00022-5","article-title":"Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia","volume":"27","author":"Tsimberidou","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2012.03.003_bib16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.790.790","volume":"114","author":"Petersdorf","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.03.003_bib17","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","article-title":"Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia","volume":"102","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.03.003_bib18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.336.336","article-title":"Frontline therapy for older patients (pts) with acute myeloid leukemia (AML): clofarabine plus low-dose cytarabine induction followed by prolonged consolidation with clofarabine plus low-dose cytarabine alternating with decitabine","volume":"116","author":"Faderl","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.03.003_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.2009.25.0209","article-title":"Phase I clinical and pharmacokinetic studhy of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.03.003_bib20","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.bjc.6605922","article-title":"Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types","volume":"103","author":"Green","year":"2010","journal-title":"Br J Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012000511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012000511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:10Z","timestamp":1761870130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012000511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S2152265012000511"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.03.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed\/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}